The Rising Demand for High-Potency ADC Payloads: Why the Supply Chain Is Being Reshaped in 2026
Antibody–drug conjugates (ADCs) continue to reshape the oncology pipeline, driven by the pursuit of payloads that can deliver stronger potency, improved tumor selectivity, and reduced systemic...